Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14433699 | 1.00 | PRMT1 (1.00) | PRMT1ADRA1AEPHX2LMNATSHR | |
| SCHEMBL2804471 | 1.00 | PRMT1 (1.00) | PRMT1ADRA1AEPHX2LMNATSHR | |
| SCHEMBL17379963 | 1.00 | PRMT1 (1.00) | PRMT1ADRA1AEPHX2LMNATSHR | |
| SCHEMBL31475477 | 0.97 | PRMT1 (0.95) | PRMT1ADRA1AEPHX2LMNATSHR | |
| SCHEMBL31475480 | 0.90 | PRMT1 (0.81) | PRMT1ADRA1AEPHX2LMNATSHR | |
| SCHEMBL29050817 | 0.89 | EPHX2 (0.81) | PRMT1EPHX2TSHREPHX1PLA2G2A | |
| SCHEMBL18724674 | 0.89 | EPHX2 (0.81) | PRMT1ADRA1AEPHX2EPHX1PLA2G2A | |
| SCHEMBL22508816 | 0.89 | PRMT1 (0.80) | PRMT1ADRA1AEPHX2LMNATSHR | |
| SCHEMBL18724795 | 0.89 | EPHX2 (0.81) | PRMT1ADRA1AEPHX2EPHX1PLA2G2A | |
| SCHEMBL15743121 | 0.89 | EPHX2 (0.81) | PRMT1ADRA1AEPHX2EPHX1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8968711-B2 | Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process | L'OREAL (FR) | 2015-03-03 | — | — | US | claimed |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | L'OREAL (FR) | 2010-10-28 | — | — | US | claimed |
| EP-4204100-A1 | HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE | L'OREAL (FR) | 2023-07-05 | — | — | EP | disclosed |
| CN-116322616-A | Hair lightening compositions providing damage protection and sensory benefits and methods of use | 欧莱雅 | 2023-06-23 | — | — | CN | disclosed |
| US-11559474-B2 | Hair lightening compositions and methods of use | L'OREAL (FR) | 2023-01-24 | — | — | US | disclosed |
| WO-2022047081-A1 | HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE | HENRY DEREK (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2018119500-A1 | VISCOELASTIC COSMETIC COMPOSITIONS | L'OREAL (FR) | 2018-07-05 | — | — | WO | disclosed |
| US-8968711-B2 | Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process | L'OREAL (FR) | 2015-03-03 | — | — | US | disclosed |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | L'OREAL (FR) | 2010-10-28 | — | — | US | disclosed |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | L'OREAL (FR) | 2010-09-23 | — | — | US | disclosed |
| US-20090028807-A1 | COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION | L'OREAL (FR) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | CUTA, SUCLG1, KRT18 | PRMT1 4663/4885ADRA1A 4844/4885EPHX2 301/4885 |
| US-20090028807-A1 | COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION | CUTA, SYMPK, TPRKB | PRMT1 2654/4885ADRA1A 4879/4885EPHX2 3893/4885 |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | ACMSD, CUTA, PCCA | PRMT1 2072/4885ADRA1A 4380/4885EPHX2 771/4885 |
| US-11559474-B2 | Hair lightening compositions and methods of use | TYR, ALAD, CYBA | PRMT1 1066/4885ADRA1A 4779/4885EPHX2 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.